NuVasive, Inc.

NasdaqGS:NUVA Lagerbericht

Marktkapitalisierung: US$2.1b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

NuVasive Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

NuVasive wird ein jährliches Gewinn- und Umsatzwachstum von 46.2% bzw. 6.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 44.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.3% betragen.

Wichtige Informationen

46.2%

Wachstumsrate der Gewinne

44.56%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum16.1%
Wachstumsrate der Einnahmen6.7%
Zukünftige Eigenkapitalrendite14.28%
Analystenabdeckung

Good

Zuletzt aktualisiert01 Sep 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Analyseartikel • Apr 18

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analyseartikel • Jan 24

What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?

While NuVasive, Inc. ( NASDAQ:NUVA ) might not be the most widely known stock at the moment, it saw a significant share...
Analyseartikel • Dec 31

NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price

Key Insights NuVasive's estimated fair value is US$60.8 based on 2 Stage Free Cash Flow to Equity Current share price...
Analyseartikel • Dec 05

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
Analyseartikel • Nov 13

These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analyseartikel • Sep 22

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

Does the September share price for NuVasive, Inc. ( NASDAQ:NUVA ) reflect what it's really worth? Today, we will...
Analyseartikel • Sep 01

Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal

When we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...
Seeking Alpha • Aug 17

NuVasive Likely Undervalued, But It's Hard To Find Catalysts

NuVasive modestly exceeded topline expectations for Q2, but core U.S. growth is still soft, particularly when factoring in the above-average growth of the cervical disc business. In a challenging spine care market, NuVasive looks at risk of "drifting", with neither the above-average revenue growth nor strong core margins that med-tech investors often seek. NuVasive isn't beyond hope - the cervical franchise looks strong, Pulse is still a long-term opportunity, and NUVA still has good overall share, but it needs to be more dynamic. The shares are undervalued below the mid-$60s, but the stock badly needs a catalyst to get investors excited about the name again. Valuation alone doesn't move stocks - expensive stocks don't fall just because they're expensive, and cheap stocks don't rise just because investors suddenly decide they're too cheap. In most cases, it requires some sort of driver or catalyst to get investors to reconsider a name, and that's a challenge for NuVasive (NUVA) today. The shares of this spine-focused medical device company do look undervalued today, but they've looked undervalued for a while. Although the shares have slightly outperformed the broader medical device space since my last update and outperformed names like Alphatec (ATEC) and SeaSpine (SPNE) while recently starting to lag Globus (GMED), they still haven't done anything to celebrate over the last five years. NuVasive is salvageable, but the company's management needs to offer more than what is apparent today - investors need to have a reason to believe in growth drivers beyond the cervical portfolio and that long-awaited margin improvement will actually materialize. While this could happen, there's a real risk that "okay, but not great" growth and margins keep a lid on the share price performance at NuVasive. Second Quarter Results - A Little Better On The Topline, But Not Really Great Overall NuVasive's second quarter was, at best, "mixed" and not really the sort of quarter that's going to shift sentiment in a meaningfully positive way. Revenue rose 8% and beat expectations by close to 2%. U.S. spine ("Hardware") revenue rose 3% on improved case volumes, and that was better than the declines at Johnson & Johnson (JNJ) and Stryker (SYK) and on pace with Globus, but with the cervical portfolio growing more than 20%, there's still weakness in the core portfolio. U.S. Surgical revenue rose 6%, with improved Pulse sales offsetting a year-over-year decline in biologics, while international sales rose more than 20% in constant currency. Gross margin declined 120bp to 72.4%, missing by 80bp, and the med-tech sector is still seeing noticeable negative impacts from supply chain issues (components, shipping, et al.). Operating income declined 1%, missing by 3%, and operating margin fell 80bp to 13.1%, missing by more than 30bp. Management basically held the line on guidance, though hitting the full year target of 9% to 11% constant currency growth is going to require acceleration from here. Ongoing post-pandemic normalization and some new product introductions can support that acceleration, but the overall U.S. spine market isn't looking especially robust right now. Waiting For Something To Disrupt The Business (In A Good Way) It's been a long, frustrating wait for real momentum in NuVasive's business, and it does explain, at least in part, why these shares have been a laggard over the longer term (five-year, 10-year, and 15-year comparisons to the sector). Revenue growth over the last 15 years hasn't been bad (around 15% a year), but that growth has slowed considerably in the last five years (to the low single digits). Salesforce defections have been a recurrent problem over the years, and relative to companies like Globus, I think you can argue that NuVasive has under-innovated, and that's taking a toll on core franchises like the lateral interbody fusion business. The company was also certainly slow to recognize the importance of robotics, and with the Pulse robotic system no longer expected to achieve first-in-human use this year, that timeline is slipping further. NuVasive has also struggled to hit even its revised operating margin targets. Where the company once talked about the possibility of 25% or better operating margins (some rivals have achieved high-20%s for margins), more recently the goal has been on the order of 20%, but the company is still well short of that - operating margin was just over 13% in the second quarter, and the most bullish sell-side projections I've seen don't call for 20% margins at any point over the next five years. On the positive side, the company's cervical disc business is growing well, and I still see strong growth potential here, as NuVasive's discs are the only ones clinically proven to produce better outcomes than fusion surgery. I also believe the full Pulse platform (not just the robotic aspect, but the planning, neuromonitoring, imaging, and navigation capabilities) can be a significant growth driver, with an addressable market opportunity of around $1.5B (against expected total revenue of around $1.2B in FY'22).
Analyseartikel • Aug 11

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Aug 03

NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M

NuVasive press release (NASDAQ:NUVA): Q2 Non-GAAP EPS of $0.47 misses by $0.09. Revenue of $310.5M (+5.3% Y/Y) beats by $4.12M.
Seeking Alpha • Jun 13

NuVasive: Industry Tailwinds More Than Fairly Priced

NuVasive has solid underpinnings as a potentially defensive play, with strengthening platform economics. Industry tailwinds also apply to the company, although it needs an above market growth pattern to adequately reward shareholders. We've priced NUVA at $49–$53 noting the stock may be fully priced at its current levels.
Analyseartikel • Jun 01

Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)

In this article we are going to estimate the intrinsic value of NuVasive, Inc. ( NASDAQ:NUVA ) by estimating the...
Analyseartikel • May 11

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Typically, we'll want...
Analyseartikel • Apr 20

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analyseartikel • Mar 30

At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?

NuVasive, Inc. ( NASDAQ:NUVA ), is not the largest company out there, but it saw a double-digit share price rise of...
Seeking Alpha • Mar 01

NuVasive's Turnaround Story Needs A Boost From Better Results

NuVasive managed a modest beat in Q4'21 and the initial guide for 2022 was okay, but the company needs to start showing clear evidence of market share regrowth. The core technology platform, including X360, is sound and newer opportunities like Simplify and Pulse can add meaningfully to revenue growth, but execution is a key unknown. Weak margins have challenged NuVasive for years, and this remains an important driver of earnings/cash flow and sentiment. NuVasive looks undervalued, but sentiment won't shift until the share losses reverse to share gains and there's evidence of positive operating leverage.
Analyseartikel • Dec 28

Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
Analyseartikel • Dec 02

Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?

NuVasive, Inc. ( NASDAQ:NUVA ), might not be a large cap stock, but it saw significant share price movement during...
Analyseartikel • Nov 11

NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analyseartikel • Oct 21

NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of NuVasive, Inc...
Analyseartikel • Sep 29

Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...
Analyseartikel • Aug 18

At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?

NuVasive, Inc. ( NASDAQ:NUVA ), is not the largest company out there, but it saw significant share price movement...
Seeking Alpha • Aug 12

NuVasive Still Getting No Love With COVID-19 And Competitive Worries

NuVasive produced its second straight quarter with a double-digit operating income beat, but in-line guidance and fears of renewed COVID-19 lockdowns seem to be weighing on the shares. New product innovation appears to be driving revenue growth, with Modulus and the cervical portfolio performing well, and Pulse about to launch. COVID-19 remains a clear short-term risk, but I believe NuVasive's opportunity to regain share and drive operating leverage is undervalued today.
Analyseartikel • Jul 27

Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analyseartikel • Jun 17

Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?

Today we will run through one way of estimating the intrinsic value of NuVasive, Inc. ( NASDAQ:NUVA ) by taking the...
Analyseartikel • May 30

Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Analyseartikel • May 12

Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All

The share price of NuVasive, Inc. ( NASDAQ:NUVA ) has increased significantly over the past few years. However, the...
Analyseartikel • Mar 30

Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analyseartikel • Mar 09

Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?

NuVasive, Inc. ( NASDAQ:NUVA ), might not be a large cap stock, but it received a lot of attention from a substantial...
Analyseartikel • Feb 16

Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Analyseartikel • Jan 26

A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)

How far off is NuVasive, Inc. ( NASDAQ:NUVA ) from its intrinsic value? Using the most recent financial data, we'll...
Analyseartikel • Jan 05

What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?

NuVasive, Inc. ( NASDAQ:NUVA ) shareholders should be happy to see the share price up 11% in the last month. But in...

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:NUVA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20251,452911142898
12/31/20241,3607310723312
12/31/20231,279386321412
6/30/20231,22628-3140N/A
3/31/20231,2192023165N/A
12/31/20221,2024030169N/A
9/30/20221,199-2027160N/A
6/30/20221,174-4044171N/A
3/31/20221,159-3738157N/A
12/31/20211,139-6470182N/A
9/30/20211,129-26103217N/A
6/30/20211,1532122232N/A
3/31/20211,062-50107212N/A
12/31/20201,051-3776186N/A
9/30/20201,069-978188N/A
6/30/20201,065-462175N/A
3/31/20201,1536196216N/A
12/31/20191,16865105235N/A
9/30/20191,14648104229N/A
6/30/20191,12752115235N/A
3/31/20191,1164989207N/A
12/31/20181,10212110219N/A
9/30/20181,08524109209N/A
6/30/20181,0604184187N/A
3/31/20181,0384277185N/A
12/31/20171,0278264177N/A
9/30/20171,0276465179N/A
6/30/20171,0193517123N/A
3/31/201799653N/A127N/A
12/31/201696237N/A158N/A
9/30/201690642N/A137N/A
6/30/201686751N/A154N/A
3/31/201683431N/A120N/A
12/31/201581166N/A89N/A
9/30/201580062N/A67N/A
6/30/201579047N/A102N/A
3/31/201577733N/A118N/A
12/31/2014762-17N/A116N/A
9/30/2014749-18N/A124N/A
6/30/2014728-9N/A113N/A
3/31/2014703-11N/A97N/A
12/31/20136858N/A97N/A
9/30/2013660-1N/A101N/A
6/30/2013639-6N/A97N/A
3/31/20136283N/A114N/A
12/31/20126203N/A130N/A
9/30/2012605-4N/A109N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: NUVADas prognostizierte Gewinnwachstum (46.2% pro Jahr) liegt über der Sparquote (2.2%).

Ertrag vs. Markt: NUVADie Erträge des Unternehmens (46.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (16.8% pro Jahr).

Hohe Wachstumserträge: NUVAEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: NUVADie Einnahmen des Unternehmens (6.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.7% pro Jahr).

Hohe Wachstumseinnahmen: NUVADie Einnahmen des Unternehmens (6.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: NUVADie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.3%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2023/09/02 06:43
Aktienkurs zum Tagesende2023/08/31 00:00
Gewinne2023/06/30
Jährliche Einnahmen2022/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

NuVasive, Inc. wird von 28 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
null nullArgus Research Company
Jeffrey JohnsonBaird
Adam FeinsteinBarclays